Applied genetic technologies corporation.
Alliance Acquisition Sub, Inc., a Delaware corporation (“Purchaser”), is offering to purchase (the “Offer”) all outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Applied Genetic Technologies Corporation, a Delaware corporation (the “Company”), at a price per Share of $0.34, to the holder in cash, without interest and less any applicable ...
Most recently, Hope was General Counsel, at Applied Genetic Technologies Corporation (AGTC), where she oversaw legal, IP and compliance. Before her tenure ...About AGTC: AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC ...View agtc (www.agtc.com) location in Florida, United States , revenue, industry and description. Find related and similar companies as well as employees by ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development ...
AGTC-501 (Applied Genetic Technologies Corporation), a novel gene therapy in development for the potential treatment of X-linked retinitis pigmentosa (RP), showed an acceptable safety profile and visual function improvements when administered in the study’s higher dose groups, according to Robert A. Sisk, MD, FACS, from the Cincinnati Eye …Company Type For Profit. Contact Email [email protected]. Phone Number +1 386-462-2204. Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They ...Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754
Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... Company Type For Profit. Contact Email [email protected]. Phone Number +1 386-462-2204. Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, …
Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... OTO-825 is the clinical candidate targeting the gap junction beta-2 (GJB2) gene developed under the company’s collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC).Applied Genetic Technologies Corp. published this content on 23 July 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 23 July 2021 17:57:04 UTC .APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware : 001-36370 : 59-3553710 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification Number) 14193 NW 119 th Terrace . Suite 10 . Alachua, Florida, 32165Feb 11, 2021 · Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754
Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Applied Genetic Technologies Corporation (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-236156), as amended (the “Registration Statement”), so that it may become effective at 4:00 pm Eastern time on …GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development ...Dec 1, 2022 · Applied Genetic Technologies Corporation (AGTC) · Syncona to invest $23.3 million upfront to acquire AGTC. · AGTC to become Syncona's third retinal gene therapy company, focused on driving AGTC-501, for X-linked retinitis pigmentosa, through late-stage clinical development. Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP ...Jun 12, 2023 · The new portfolio company has been created by Syncona through the combination of Applied Genetic Technologies Corporation’s (AGTC’s) late-stage programme in X-linked retinitis pigmentosa (XLRP), with two other innovative pre-clinical programmes. Applied Genetic Technologies Corporation T: (617) 843-5778 [email protected] ...
Nov 3, 2022 · Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ... GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a …Applied Genetic Technologies Corporation (AGTC) · Syncona to invest $23.3 million upfront to acquire AGTC. · AGTC to become Syncona's third retinal gene therapy company, focused on driving AGTC-501, for X-linked retinitis pigmentosa, through late-stage clinical development.Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same quarter last year, the firm posted ($0.60) earnings per share.Purpose: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal disease caused by mutations in the RS1 gene. Design: Open-label, phase I or II dose-escalation clinical trial. Subjects: Twenty-two adults and 5 children with X-linked retinoschisis …Applied Genetic Technologies Corporation, a Cambridge- and Florida-based gene therapy firm better known as AGTC could go private through an acquisition …
Syncona to Acquire Applied Genetic Technologies Corporation. Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on ...Applied Genetic Technologies Corporation (the “Company” or “AGTC”) was incorporated as a Florida corporation on January 19, 1999 and reincorporated as a Delaware corporation on October 24, 2003.On June 7, 2022, Applied Genetic Technologies Corporation (the "Company") received written notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Listing …GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology ...Applied Genetic Technologies Corporation 2013 Employee Stock Purchase Plan (Full titles of plans) Susan B. Washer . President and Chief Executive Officer . Applied Genetic Technologies Corporation . 14193 NW 119th Terrace, Suite 10 . Alachua, Florida 32615 (386) 462-2204Dec 14, 2021 · Applied Genetic Technologies Corporation (NASDAQ: AGTC) is a Florida based clinical stage biotech concern. The company is focused on developing transformational genetic therapies for patients ... Aug 25, 2020 · Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 Applied Genetic Technologies Corp. published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 18:24:09 UTC.Applied Genetic Technologies is not a large company by global standards. It has a market capitalization of US$122m, which means it wouldn't have the attention of many institutional investors.
29 jui. 2023 ... Applied Genetic Technologies Corporation; Developer Beacon Therapeutics; National Heart, Lung and Blood Institute; Class Gene therapies ...
Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ...
Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan LieberGAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a …APPLIED GENETIC TECHNOLOGIES CORP : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in …Company Type For Profit. Contact Email [email protected]. Phone Number +1 386-462-2204. Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They ...Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC ...Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected] ...Applied Genetic Technologies Corp: ClinicalTrials.gov Identifier: NCT02416622 Other Study ID Numbers: AGTC-RS1-001 : First Posted: April 15, 2015 Key Record Dates: Results First Posted: July 1, 2020: Last Update Posted: June 12, 2023 Last Verified: June 2023
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development ...1. According to the release, Syncona Limited partnered with additional investors including OSE to provide the new therapeutic venture with £96 million ($120 million) in funding. In November 2022, Syncona acquired Applied Genetic Technologies Corporation (AGTC). Beacon Therapeutics called AGTC-501, a gene therapy program currently in Phase II ...Syncona to Acquire Applied Genetic Technologies Corporation. Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on ...In today’s digital age, technology has made many aspects of our lives more convenient and efficient. One area where this is especially true is the application process for government assistance programs, such as food stamps.Instagram:https://instagram. edward h bastianstock c3.aihow do i read stock chartsbyd ev stock Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber best prop firm forextdf fund Feb 11, 2021 · Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 what time iphone 15 pre order Oct 24, 2022 · Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ... Applied Genetic Technologies Corporation, a Cambridge- and Florida-based gene therapy firm better known as AGTC could go private through an acquisition …GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the ...